Moleculin Biotech Regains Nasdaq Listing Compliance; Delisting Hearing Canceled
Benzinga Newsdesk 10 months ago
News
As previously disclosed, on May 23, 2025, Moleculin Biotech, Inc. (the "Company") received a letter from the staff of the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq"), which
As previously disclosed, on May 23, 2025, Moleculin Biotech, Inc. (the "Company") received a letter from the staff of the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq"), which notified the Company that it did not comply with Nasdaq's Listing Rule 5550(b)(1) (the "Listing Rule"), which requires that the Company maintain a minimum of $2.5 million in stockholders' equity, and that the Company also did not meet the alternatives of market value of listed securities or net income from continuing operations set forth in the Listing Rule.
On November 20, 2025, the Company received a delist determination letter from the Staff advising the Company that the Staff had determined that the Company had not regained compliance with the Listing Rule, and the Company subsequently requested a hearing panel (a "Panel") appeal of the delist determination.
On January 6, 2026, the Staff informed the Panel that the Company had regained compliance with the Listing Rule and that the Company is in compliance with all applicable continued listing standards. As such, the hearing before the Panel has been cancelled.